Canagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that promotes urinary glucose excretion to lower blood sugar in type 2 diabetes, with additional demonstrated cardiovascular and renal-protective benefits. Simson Pharma's Canagliflozin reference standard and impurities support generic development and stability-indicating testing in this rapidly growing antidiabetic class.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Canagliflozin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.